Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of DSIP and SS-31 — mechanism, side effects, legal status, and pricing.
DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) isolated in 1977 by Schoenenberger and Monnier from cerebral venous blood of rabbits during electrically induced sleep. It has been studied as a putative sleep and stress modulator, but the evidence base is weak, largely pre-2000, and DSIP is not FDA-approved.
SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) developed by Hazel Szeto (Cornell) and clinically advanced by Stealth BioTherapeutics. It concentrates in the inner mitochondrial membrane by binding cardiolipin. In September 2025, the FDA granted accelerated approval to elamipretide (brand name FORZINITY) as the first therapy for Barth syndrome — the first FDA-approved mitochondria-targeted drug. It remains investigational for other indications.
DSIP
SS-31
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
DSIP
SS-31
COA corpus from Disclosed Labs — independently tested batches only.
DSIP
69
COAs
99.4%
Avg purity
14
Labs
SS-31
65
COAs
99.8%
Avg purity
12
Labs
DSIP is among peptides under FDA review for the Category 1 (503A) list; if added, it would require a prescription to be compounded by registered 503A/503B pharmacies — not yet authorized. SS-31 remains research-only. In April 2026 the FDA removed 12 peptides from Category 2, which does not place them on the Category 1 list or authorize compounding. The FDA's Pharmacy Compounding Advisory Committee is advisory and meets July 23–24, 2026 to review nominations and make recommendations to the FDA.
Schoenenberger & Monnier first isolated and characterized DSIP in 1977 (PNAS 74(3):1282-6, PMID 265572). Graf & Kastin's 1984 review (Neurosci Biobehav Rev, PMID 6145137) summarized the first decade of work, noting reported effects on sleep, pain, and stress but also substantial inconsistency across labs and species. Schneider-Helmert (Eur Neurol 1986, PMID 3792404) reported sleep normalization in 18 middle-aged and elderly chronic insomniacs given DSIP over one week — small, open, and never replicated at scale. Schneider-Helmert et al. (Dtsch Med Wochenschr 1987, PMID 3582201) explored phase-shifted insomnia. Kovalzon & Strekalova (J Neurochem 2006, PMID 16539679) summarized the field as a 'still unresolved riddle,' noting that no DSIP receptor or gene has been identified. No Phase 3 trials, no FDA approval, no modern controlled replication.
Key references
The original SS-peptide class was described by Zhao, Szeto and colleagues (J Biol Chem 2004, PMID 15178689), showing ~1000-fold concentration at the inner mitochondrial membrane and protection against oxidative cell death. Szeto's 2014 review (Br J Pharmacol, PMID 24117165) reframed the mechanism as cardiolipin-binding rather than antioxidant scavenging. The TAZPOWER trial (NCT03098797) in Barth syndrome, with its 168-week open-label extension (Thompson et al., Genet Med 2024, PMID 38602181), supported FDA accelerated approval of FORZINITY in September 2025 at 40 mg SubQ daily. The Phase 3 MMPOWER-3 trial in primary mitochondrial myopathy (Karaa et al., Neurology 2023, PMID 37268435) FAILED co-primary endpoints of 6-minute walk test and fatigue score, though a post-hoc nuclear-DNA subgroup showed improvement. Phase 2 ReCLAIM-2 in geographic atrophy missed primary endpoints but reduced ellipsoid-zone attenuation; a Phase 3 trial is ongoing. Earlier heart failure trials (PROGRESS-HF) showed only modest signals.
DSIP (Cognitive) and SS-31 (Recovery) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs